Reportlinker Adds Respiratory Therapeutics and Devices Markets
NEW YORK, April 26, 2011 /PRNewswire/ -- Reportlinker.com announces that a new market research report is available in its catalogue:
Respiratory Therapeutics and Devices Markets
http://www.reportlinker.com/p0486614/Respiratory-Therapeutics-and-Devices-Markets.html
In the respiratory therapeutics and devices market, continuing new advancements in the ability to detect and manage respiratory diseases are being made. The respiratory disease space is one of the most profitable sectors of therapeutics, and it is expected to be growing vigorously into the future. This TriMark Publications report analyzes various respiratory therapeutics and devices markets, with special attention paid to therapeutic remedies for chronic obstructive pulmonary disease (COPD), asthma and cystic fibrosis. Also addressed in this study are therapeutics for upper respiratory infections such as: allergic rhinitis, influenza, respiratory syncytial virus, sinusitis, and pharyngitis/tonsillitis. From respiratory devices side, key segments covered include: continuous positive airway pressure (CPAP) devices, ventilators, nebulizers, oxygen concentrators, humidifiers and reusable resuscitators. This review covers the leading market players, the competitive landscape, and the emerging pipeline products in the respiratory therapeutics and devices markets. Specifically, areas examined in this study include: available and developing technologies in the field, the U.S. and global market size for respiratory therapeutic products, and the profiles of companies that are focusing on the respiratory therapeutics and devices market. This review analyzes the size and growth of the therapeutic respiratory disease category, including the factors that influence the various market segments within it. Detailed charts with sales forecasts and market share data for the U.S. and global respiratory therapeutics and devices markets are included.
TABLE OF CONTENTS
1. Overview 8
1.1 Statement of Report 8
1.2 About This Report 8
1.3 Scope of the Report 9
1.4 Objectives 11
1.5 Methodology 12
1.6 Executive Summary 13
2. Respiratory Epidemiological Analysis 21
2.1 COPD 21
2.1.1 Background and Pathogenesis 25
2.1.2 Diagnosis and Staging of COPD 28
2.1.3 COPD Management 29
2.1.4 COPD Therapeutics 30
2.1.4.1 Bronchodilators 30
2.1.4.2 Beta Agonists 30
2.1.4.3 Anticholinergics 30
2.1.4.4 Methylxanthines 30
2.1.4.5 Corticosteroids 31
2.1.4.6 Combination Therapies 31
2.1.5 Inhaled Medication Delivery Systems 31
2.1.6 Economic Cost of COPD 32
2.2 Asthma 34
2.2.1 Background and Pathogenesis 39
2.2.2 Molecular Mechanisms of Asthma 40
2.2.3 Risk Factors Related to Disease 41
2.2.4 Exacerbating Factors 41
2.2.4.1 Allergens 42
2.2.4.2 Infections 42
2.2.4.3 Exercise 42
2.2.4.4 Nonsteroidal Anti-inflammatory Drugs 42
2.2.4.5 Gastroesophageal Reflux 42
2.2.4.6 Psychosocial Factors 42
2.2.5 Asthma Management and Prevention 43
2.2.6 Asthma Treatment 43
2.2.6.1 Short-Acting Beta-Agonists 43
2.2.6.2 Inhaled Corticosteroids 44
2.2.6.3 Long-Acting Beta-Agonists 44
2.2.6.4 Oral Glucocorticosteroids 44
2.2.7 Single Maintenance and Reliever Therapy (SMART) 44
2.2.8 Immunotherapy for Asthma 45
2.2.9 Economic Burden of Asthma 45
2.3 Upper Respiratory Infections 48
2.3.1 Allergic Rhinitis 48
2.3.2 Influenza 49
2.3.3 Respiratory Syncytial Virus 53
2.3.4 Sinusitis 53
2.3.5 Pharyngitis/Tonsillitis 54
2.3.6 Economic Cost of Upper Respiratory Infections 55
2.4 Cystic Fibrosis 56
2.4.1 Background and Pathophysiology 58
2.4.2 Cystic Fibrosis Treatment and Management 60
2.4.3 New therapies for Cystic Fibrosis 62
2.4.3.1 Gene Therapy for Cystic Fibrosis 63
2.4.3.2 Novel CFTR Modulation 64
2.4.3.3 Anti-inflammatory Cystic Fibrosis Therapy 64
2.4.3.4 Anti-infective Agents in Cystic Fibrosis 65
2.4.3.5 Mucoactive Agents in Cystic Fibrosis 65
2.4.4 Economic Burden of CF 65
3. Major Drug Classes in Treating Respiratory Diseases 67
3.1 Leukotriene Inhibitors 67
3.2 Corticosteroids 68
3.3 Beta-2 (Adrenmoreceptor) Agonists 69
3.4 Antihistamines 69
3.5 Monoclonal Antibodies 70
4. Global Market Analysis—Leading Therapeutics and Players 71
4.1 COPD Market Analysis 71
4.1.1 Leading Therapeutics in COPD market 74
4.1.2 Main Players in COPD 75
4.1.3 COPD Market Forecast 78
4.1.3.1 Revenue Forecasts 78
4.1.3.2 Market Drivers 78
4.1.3.3 Market Restraints 78
4.1.4 Market and Technology Trends 79
4.2 Asthma Market Analysis 79
4.2.1 Leading Therapeutics in Asthma 80
4.2.2 Main Players in Asthma 82
4.2.3 New Asthma Therapeutics 83
4.2.4 Asthma Market Forecast 83
4.2.4.1 Revenue Forecasts 83
4.2.4.2 Market Drivers 84
4.2.4.3 Market Restraints 84
4.2.4.4 Market and Technology Trends 84
4.3 Cystic Fibrosis Market Analysis 85
4.3.1 Leading Therapeutics in Cystic Fibrosis 86
4.3.2 Main Players in Cystic Fibrosis 86
4.3.3 Cystic Fibrosis Market Forecast 87
4.3.3.1 Market Drivers 87
4.3.3.2 Market Restraints 87
4.3.3.3 Market and Technology Trends 87
4.4 Respiratory Syncytial Virus Market Analysis 88
4.4.1 Immunoprophylatic Antibody Market Analysis 90
4.4.2 RSV Vaccine Market 90
4.4.3 RSV Antiviral Market Analysis 90
4.5 Allergic Rhinitis Market Analysis 91
4.5.1 Intranasal Corticosteroid Market 91
4.5.2 Antihistamine Market 92
4.5.3 Over-the-Counter Market 92
5. The Respiratory Pipeline—Analysis of Future Therapeutics 93
5.1 The COPD Market 93
5.1.2 Upcoming COPD Therapeutics 93
5.1.2.1 Phosphodiesterase Inhibitors 94
5.1.2.2 Long-Acting Muscarinic Antagonists 95
5.1.2.3 Long-Acting Beta-Agonists 95
5.1.2.4 Mediator Antagonists 95
5.1.2.5 Leukotriene-B4 Inhibitors 96
5.1.2.6 Chemokine Inhibitors 96
5.2 The Asthma Market 97
5.2.1 Upcoming Asthma Therapeutics 98
5.2.1.1 Bronchodilators 98
5.2.1.2 Corticosteroids 98
5.2.1.3 Cytokine Blockers 99
5.2.1.4 Chemokine Antagonists 99
5.2.1.5 Phosphodiesterase Inhibitors 99
5.2.1.6 Kinase Inhibitors 100
5.2.1.7 Mast Cell Inhibitors 100
5.3 The Cystic Fibrosis Market 101
5.3.1 Upcoming Cystic Fibrosis Therapeutics 102
5.4 Influenza Market 103
5.4.1 Upcoming Influenza Treatments 108
5.4.1.1 Adjuvant Technology 108
5.4.1.2 Improving Manufacturing Techniques 108
6. The Respiratory Care Devices Market 110
6.1 Aerosol Generation and Efficient Delivery 110
6.2 Medication Delivery Systems 111
6.3 Nebulizers 112
6.3.1 Nebulizer Market Grows 114
6.3.2 Portable, Compact and Noiseless Nebulizers—Gain Popularity 115
6.4 Dry Powder Inhalers 115
6.5 Pressurized Metered-Dose Inhalers 116
6.6 Ventilators Market 117
6.7 Pulmonary Function Testing Equipment—Spirometry 118
6.8 Sleep Apnea Therapeutic Devices Market—CPAP/Bi-level Devices 119
6.8.1 CPAP Equipment Gain Popularity in the Pre-Hospital Setting 121
6.9 Humidifiers 121
6.10 Oxygen Equipment 122
6.11 Reusable Resuscitators 123
7. Respiratory Care Industry Market Analysis 128
7.1 Medication Delivery System Market Analysis 128
7.2 Medical Ventilator Market analysis 130
7.3 Pulmonary Function Test Market Analysis 131
7.4 Continuous Positive Airway Pressure Therapy Market Analysis 132
7.5 Humidifier Market Analysis 134
7.6 Long Term Oxygen Treatment Market Analysis 135
7.7 Reimbursement Cuts Negatively Affect the Respiratory Market 135
7.8 Growing Incidence Rates for Respiratory Disorders to Propel Demand for
Respiratory Devices 137
7.9 Availability of Reimbursement in the U.S. to Drive Sales of Respiratory
Devices 137
7.10 Growth in Home Healthcare to Result in Increased Demand for Respiratory
Devices in the Future 137
7.11 Development of Technologically Advanced and User Friendly Systems to
Increase Adoption of Respiratory Devices 138
8. SWOT Analysis of the Respiratory Market 141
8.1 Biopharmaceutical Industry—Key Aspects of 2010 141
8.2 Main Drivers for Respiratory Therapeutics 143
8.3 Main Restraints for Respiratory Therapeutic and Device Market 144
8.4 Challenges of Respiratory Therapeutics and Devices Going Forward 146
8.5 An Emerging Market: Focus on Chinese Health Biotechnology Market 148
8.6 Summary of Market Strengths, Weaknesses, Opportunities and Threats 150
9. Major Players in the Respiratory Market 152
9.1 Aerogen 152
9.2 Altana AG 152
9.3 Aradigm 152
9.4 AstraZeneca 152
9.5 Boehringer Ingelheim 152
9.6 CareFusion 153
9.7 Covidien 153
9.8 DeVilbiss Healthcare 154
9.9 Drager 154
9.10 Fisher & Paykel Healthcare 154
9.11 GlaxoSmithKline 154
9.12 Merck & Co. 155
9.13 Nektar Therapeutics 156
9.14 Novartis 156
9.15 Pfizer 157
9.16 ResMed 158
9.17 Respironics 158
9.18 Roche 158
9.19 Schering-Plough 158
9.20 Sepracor 158
INDEX OF FIGURES
Figure 1.1: Smoking Culture Segmentation of the U.S. Population 16
Figure 1.2: Smoking Trends of U.S. Male and Female Population 16
Figure 1.3: Current Smoking Trends in U.S. by Ethnicity 17
Figure 2.1: COPD is the Fourth Main Killer in the U.S., 2006 21
Figure 2.2: COPD Death Rates in the U.S., 1999-2006 22
Figure 2.3: Age-standardized Death Rate for COPD in the U.S., 1999-2006 22
Figure 2.4: Chronic Bronchitis in the Lungs 25
Figure 2.5: Emphysema of the Lungs 26
Figure 2.6: Pulmonary and Systemic Inflammation in Acute COPD Exacerbations 27
Figure 2.7: Management of Patients with Moderate to Severe Exacerbations of COPD
29
Figure 2.8: Economic Impact of COPD 33
Figure 2.9: International Asthma Prevalence Ranking 34
Figure 2.10: Percentage Asthma Prevalence in the U.S. 35
Figure 2.11: Self-reported Lifetime Asthma Prevalence Rate by State in the U.S.
35
Figure 2.12: Self-reported Current Asthma Prevalence Rate by State in the U.S.
36
Figure 2.13: Ratio of Adult Self-reported Current to Lifetime Asthma by State in
the U.S. 37
Figure 2.14: Asthma Prevalence by Age, Sex and Race in the U.S. 38
Figure 2.15: Prevalence of Current Asthma among Persons of All Ages in the U.S.,
2001-2009 38
Figure 2.16: Prevalence of Current Asthma among Persons of All Ages by Age Group
and
Sex in the U.S., 2009 39
Figure 2.17: The Epithelial-Mesenchymal Trophic Unit in Asthma 40
Figure 2.18: Stepwise Asthma Treatment 43
Figure 2.19: Economic Burden of Asthma on U.S. Economy, 1992-2010 46
Figure 2.20: Percentage of Diagnostic Tests Used by Healthcare Providers to
Diagnose Allergic
Rhinitis in Children 48
Figure 2.21: Percentage of Allergic Rhinitis Incidence by Season 49
Figure 2.22: Top Triggers of Allergic Rhinitis in Population 49
Figure 2.23: Percentage of Respiratory Specimens that Tested Positive for
Influenza, October 2010 50
Figure 2.24: Geographic Areas with Confirmed Human Cases of H5N1 Avian Influenza
since
January 2010 51
Figure 2.25: Number of Reported and Confirmed Cases of Influenza H1N1 Strain
Worldwide 52
Figure 2.26: Detailed Structure of the Throat and Pharynx 55
Figure 2.27: Prevalence of Cystic Fibrosis in the U.S. and Europe 57
Figure 2.28: European Prevalence per 10,000 Population of Cystic Fibrosis 58
Figure 2.29: Cystic Fibrosis Transmembrane Conductance Regulator (CFTR)
Structure 59
Figure 2.30: Pathogenesis of Cystic Fibrosis 60
Figure 3.1: Leukotriene Inhibitor Biochemical Pathway 67
Figure 3.2: Corticosteroid Biosynthetic Endogenous Pathway 68
Figure 4.1: Global Pharmaceutical Sales, 2008-2010 71
Figure 4.2: Global Segmentation of Pharmaceutical Sales, 2009 72
Figure 4.3: Percentage of World Market by Geographic Region 72
Figure 4.4: COPD Market Percentage Share by Country Market 73
Figure 4.5: Global Advair Sales by Market, 2010 73
Figure 4.6: Prescription Respiratory World Market Share Differentiated by
Disease State 74
Figure 4.7: Worldwide Prevalence of COPD 75
Figure 4.8: Top Blockbuster COPD Therapeutics Global Sales, 2009 76
Figure 4.9: Percentage Market Share of Leading Asthma Pharmaceuticals 80
Figure 4.10: Top Selling Global Asthma Therapeutics 81
Figure 4.11: Global Sales of the Major Players in the Asthma Market 82
Figure 4.12: Cystic Fibrosis Market Forecast, 2010 and 2015 85
Figure 4.13: Potential Patient Pool requiring Respiratory Syncytial Virus
Treatment 89
Figure 4.14: Market Dynamics of Main Respiratory Syncytial Virus Therapeutic
Agents, 2007-2015 90
Figure 4.15: Global Market Segmentation of Allergic Rhinitis 91
Figure 5.1: Market Share of Specific Therapeutic Classes for COPD, 2002-2007 93
Figure 5.2: Percentage Share of Novel COPD Therapeutics in Clinical Development,
2009 94
Figure 5.3: Mechanisms by which Sensitized Mast Cells can be Inhibited in Asthma
101
Figure 5.4: Major Market Forecast for Cystic Fibrosis Therapeutics, 2010 and
2015 102
Figure 5.5: Prevalence of Cystic Fibrosis Patients in Major Markets 102
Figure 5.6: Global Influenza Market Segmentation, 2007-2014 104
Figure 5.7: Vaccine Sales of Major Pharmaceutical Companies, 2009 104
Figure 5.8: Vaccine Providers and Number of Doses Provided for the U.S. Market:
The 2000/2001 to 2008/2009 Influenza Season 105
Figure 5.9: U.S. Vaccine Supply versus Demand for Influenza Seasons 2003/2004 to
2008/2009 106
Figure 5.10: U.S. Population Recommended Receiving the Influenza Vaccine for
Seasons 2003/2004 to
2008/2009 106
Figure 5.11: Percentage of Influenza Vaccine Doses Produced that were
Distributed for Seasons 2003/2004 to 2008/2009 107
Figure 5.12: Seasonal Influenza Vaccine Market Size and Forecast, 2005/2006 to
2012/2013 107
Figure 6.1: Number of Models of Reusable Resuscitators According to Price Range
124
Figure 6.2: Distribution of Resuscitator Manufacturers Globally 124
Figure 7.1: Market Segmentation for Resmed Sales, 2008-2010 133
Figure 7.2: Percentage Sales by Geographic Region, Fisher & Paykel, 2010 134
Figure 8.1: Number of Approved Biopharmaceuticals in Five Major Markets,
1998-2009 141
Figure 8.2: Projected Replacement Ratios for Large Pharmaceutical Companies 145
Figure 8.3: Total Number of Biopharmaceutical Deals, 2007-2010 146
INDEX OF TABLES
Table 1.1: Key Facts on Chronic Obstructive Pulmonary Disease (COPD) 18
Table 1.2: Key Facts on Asthma 19
Table 2.1: Chronic Obstructive Pulmonary Disease: Estimated Prevalence by
Current Occupation and Smoking Status, U.S. Females Age 18 and Over, 1997-2004
23
Table 2.2: Chronic Obstructive Pulmonary Disease: Estimated Prevalence by
Current Occupation and Smoking Status, U.S. Males Age 18 and Over, 1997-2004 24
Table 2.3: COPD Risk Factors Source GOLD 28
Table 2.4: GOLD Criteria for COPD Staging Based on Post-Bronchodilator FEV1 28
Table 2.5: Primary indications of COPD Pathogenesis Source GOLD 28
Table 2.6: Inhaled Corticosteroids Used in the Management of COPD 31
Table 2.7: Advantages and Disadvantages of Inhaled Delivery Systems for COPD 31
Table 2.8: Top COPD Inhalers on the Market 32
Table 2.9: Symptoms of Asthma 39
Table 2.10: Triggers of Asthma 40
Table 2.11: Symptoms of an Asthma Attack 41
Table 2.12: Exacerbating Factors that may lead to an Asthma Attack 41
Table 2.13: Mechanisms of Allergen Immunotherapy 45
Table 2.14: Economic Cost of Asthma in the U.S., 2010 46
Table 2.15: International Costings of Asthma Exacerbations by Disease Severity
47
Table 2.16: Main Symptoms of Patients with Cystic Fibrosis 57
Table 2.17: Classifications of Mutations Attributed to Cystic Fibrosis 59
Table 2.18: Age-specific Presentations of Cystic Fibrosis 61
Table 2.19: Cystic Fibrosis Disease Management 61
Table 2.20: Current Respiratory Treatment for Cystic Fibrosis 62
Table 2.21: Key Novel Cystic Fibrosis Therapeutics 62
Table 2.22: Drug Development Pipeline Funded by the Cystic Fibrosis Foundation
63
Table 4.1: Common Beta-2 Agonist Treatments for COPD 77
Table 4.2: Common Anticholinergic Treatments for COPD 77
Table 4.3: Common Inhaled Glucocorticosteroid Treatments for COPD 77
Table 4.4: Combination Short-Acting Beta-2 Agonist and Anticholinergic Treatment
for COPD 77
Table 4.5: Combination Short-Acting Beta-2 Agonist and Inhaled
Glucocorticosteroid
Treatment for COPD 77
Table 4.6: Global Market Forecast for the COPD/Asthma Market, 2011-2019 78
Table 4.7: COPD Market—Market Drivers Ranked in Order of Impact 78
Table 4.8: COPD Market—Market Restraints Ranked in Order of Impact 78
Table 4.9: What to Expect from the COPD Market 79
Table 4.10: Global Market Forecast for the COPD/Asthma Market, 2011-2019 83
Table 4.11: Asthma Market—Market Drivers Ranked in Order of Impact 84
Table 4.12: Asthma Market—Market Restraints Ranked in Order of Impact 84
Table 4.13: What to Expect from the Asthma Market 85
Table 4.14: Cystic Fibrosis Market—Market Drivers Ranked in Order of Impact 87
Table 4.15: Cystic Fibrosis Market—Market Restraints Ranked in Order of Impact
87
Table 4.16: What to Expect from the Cystic Fibrosis Market 88
Table 4.17: Pipeline Therapeutics against Respiratory Syncytial Virus 89
Table 5.1: New COPD Mediator Antagonist Therapeutics in Clinical Development 96
Table 5.2: COPD Pipeline Therapeutics Currently in Development 97
Table 5.3: Recent Deals between Major Vaccine Pharmaceutical Companies and
Domestic Companies in Emerging Markets 105
Table 6.1: Global Respiratory Devices Market Growth Forecast, 2009-2016 110
Table 6.2: Factors that Promote Inefficient Aerosol Delivery in Children 111
Table 6.3: Advantages and Disadvantages of Respiratory Medication Delivery
Systems 111
Table 6.4: Aerosol Therapeutics Available or Under Development 112
Table 6.5: Inhalation Therapeutics Available for Nebulizer Use 113
Table 6.6: New Generation Nebulizers 113
Table 6.7: Dry Powder Inhalers on the Market 116
Table 6.8: Pressurized Metered Dose Inhalers on the Market 117
Table 6.9: Mechanisms of Action of Continuous Positive Airway Pressure (CPAP)
120
Table 6.10: Advantages and Disadvantages of Non-invasive Positive Pressure
Ventilation 120
Table 6.11: CPAP Device Considerations for the Pre-Hospital Setting 121
Table 6.12: Types of Humidifiers Available on the Market 122
Table 6.13: Challenges to Oxygen Delivery Technology 123
Table 6.14: Resuscitator Manufactures in China and Taiwan 125
Table 6.15: Resuscitator Manufactures in Europe 125
Table 6.16: Resuscitator Manufactures in India 125
Table 6.17: Resuscitator Manufactures in the U.K. 126
Table 6.18: Resuscitator Manufactures in the U.S. 126
Table 6.19: Price Comparison of Reusable Resuscitators on the Market 127
Table 7.1: Key Factors Driving the Respiratory Care Industry 128
Table 7.2: Key Drivers of the Global Ventilator Market 130
Table 7.3: Key Growth Factors in the Sleep Apnea Therapeutic Devices Market 132
Table 7.4: Key Restraints in the Sleep Apnea Therapeutic Devices Market 133
Table 7.5: Economic and Geographic Determinants of Global Reimbursement Cuts 135
Table 7.6: Hospital Costs due to Reimbursement Changes in Healthcare Reform Law
136
Table 7.7: Growing Incidence Rates for Respiratory Disorders 137
Table 8.1: Top Ten Selling Biopharmaceuticals, 2009 142
Table 8.2: Top Ten Biopharmaceutical Drops, 2010 142
Table 8.3: Key Merger and Acquisition Deals, 2010 143
Table 8.4: BioPharmaceutical Therapeutics Facing Patent Expiration in the U.S.
144
Table 8.5: Potential Challenges of Respiratory Therapeutics and Device Market
146
Table 8.6: Ones to Watch—Chinese Biopharmaceutical Companies on the Up 149
Table 8.7: Summary of Strengths, Weaknesses, Opportunities and Threats of
Respiratory Market 151
To order this report:
: Respiratory Therapeutics and Devices Markets
Check our Company Profile, SWOT and Revenue Analysis!
CONTACT:
Nicolas Bombourg
Reportlinker
Email: [email protected]
US: (805)652-2626
Intl: +1 805-652-2626
SOURCE Reportlinker
Share this article